A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

Phase 1 Active not recruiting 196 enrolled Arcus Biosciences, Inc.

RandomizedSequentialOpen-labelTreatment

Summary

This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants with advanced pancreatic cancer.

Timeline

Start: 2019-11-06
Primary completion: 2027-05
Completion: 2027-05

Publications

Wainberg ZA, Manji GA, Bahary N, Ulahannan SV, Pant S, Spigel DR, Uboha NV, Oberstein PE, Saeed A, Beagle B, Kim JY, Wang N, Weeder B, Shitole S, Mrouj K, Scott JR, Ensign LG, DiRenzo DM, Walters MJ, Wu W, Kaplan A, Cho S, Kabbarah O, O'Reilly EM. Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial. Nat Med. 2026 Apr;32(4):1267-1277. doi: 10.1038/s41591-026-04283-z. Epub 2026 Mar 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Quemliclustat	Small molecule	25 mg	Intravenous
Subject	Quemliclustat	Small molecule	50 mg	Intravenous
Subject	Quemliclustat	Small molecule	75 mg	Intravenous
Subject	Quemliclustat	Small molecule	100 mg	Intravenous
Subject	Quemliclustat	Small molecule	125 mg	Intravenous
Subject	Zimberelimab	Monoclonal antibody	—	Intravenous
Background	Gemcitabine	Small molecule	—	Intravenous
Background	Paclitaxel	Small molecule	—	Intravenous

A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

Summary

Timeline

Publications

Drugs

Indications